Private Equity, VC & Investor
First Analysis vs Index Ventures
Structured technology and market comparison · 2026
Direct Feature Comparison
First Analysis · vs · Index VenturesVenture capital and transaction advisory for B2B tech companies.
Venture capital firm investing in technology companies.
Analyze all overlapping signals and tech stacks for First Analysis and Index Ventures
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between First Analysis and Index Ventures?
When comparing First Analysis and Index Ventures, both platforms operate within the Private Equity, VC & Investor ecosystem. First Analysis is positioned as Venture capital and transaction advisory for B2B tech companies, whereas Index Ventures focuses on Venture capital firm investing in technology companies. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to First Analysis and Index Ventures?
When evaluating First Analysis and Index Ventures, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of First Analysis and Index Ventures compare?
First Analysis is headquartered in United States (founded in 1981) with 10–49 employees. Index Ventures is based in United Kingdom (founded in 1996) with 50–200 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: First Analysis vs Index Ventures
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
First Analysis
Recent Signals
- ·First Analysis
First Analysis acted as the exclusive financial advisor to Phigenics in its majority growth investment from Battery Ventures
First Analysis acted as the exclusive financial advisor to Phigenics, a healthcare-focused water risk management platform, in its majority growth investment from Battery Ventures. The partnership aims to support Phigenics' growth through increased investment in existing and new products, as well as expansion into new markets. Phigenics serves more than 250 customer organizations, including major hospital systems and VA facilities, and operates accredited laboratories in Illinois and Arkansas.
- On September 24, 2026, First Analysis announced it acted as exclusive financial advisor to Phigenics in a majority growth investment from Battery Ventures.
- Phigenics is a healthcare-focused water risk management platform serving more than 250 customer organizations, including major hospital systems and VA facilities.
- Phigenics is headquartered in Warrenville, Illinois, with accredited laboratories in Warrenville and Fayetteville, Arkansas.
Index Ventures
Recent Signals
- ·Tech.eu (European Tech & Deals)Financials
Iwoca CEO Discusses 15 Years in Fintech, SME Loans, Sale
In an interview, Christoph Rieche, CEO and co-founder of UK SME lender Iwoca, reflects on the company's 15-year journey, its growth, and a possible sale. Iwoca, which raised around £70m in equity and is backed by Augmentum and CommerzVentures, was reported by Sky News in June to be up for sale with a valuation over £1bn, having hired Qatalyst Partners. Rieche confirms shareholders are seeking liquidity but says it won't impact strategy. The company's loan origination rose to £1.5bn in 2025, with revenues up 56% to £366m and profits nearly doubling to £113m. Iwoca has recently expanded into credit scores, business credit cards, and an M&A platform. It also announced a partnership with Starling. Rieche also addressed a sanctioned shareholder issue that was resolved. He noted London has become less attractive for fintechs but remains Iwoca's headquarters.
- Iwoca, a UK SME lender, is reportedly up for sale with a valuation of over £1bn.
- Iwoca raised £70m in equity and is backed by Augmentum and CommerzVentures.
- Iwoca's loan origination reached £1.5bn in 2025, with revenues up 56% to £366m and profits at £113m.
- ·techcrunchVenture Capital
Investors Warn of 2027 Correction, Offer Series A Advice
At TechCrunch Disrupt, three venture investors discussed the current Series A fundraising environment. Shailendra Singh of Peak XV, Jahanvi Sardana of Index Ventures, and Janelle Teng Wade of Bessemer cautioned founders about market froth, inflated metrics, and the potential for a correction by 2027. They noted that rounds are increasingly being split into tranches, a trend they call 'tranchopalooza.' Investors are focusing on sectors like defense, robotics, and AI infrastructure. Teng Wade highlighted that early-stage AI companies may have negative margins but can still attract investment if the market opportunity is huge. The panel advised founders to be honest in their pitch, avoid cumulative revenue charts, and be audacious in their asks, while also being careful not to build solely based on what is currently being funded.
- Shailendra Singh of Peak XV warned of a market correction by 2027.
- The term 'tranchopalooza' was coined to describe rounds split into tranches.
- Investors highlighted defense, robotics, and AI infrastructure as hot sectors.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners First Analysis and Index Ventures share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks